The stock of Sage Therapeutics Inc. (NASDAQ:SAGE) last traded at $44.42, up 9.01% from the previous session.
Data from the available sources indicates that Sage Therapeutics Inc. (NASDAQ:SAGE) is covered by 22 analysts. The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $105.00 and a low of $36.00, we find $50.00. Given the previous closing price of $40.75, this indicates a potential upside of 22.7 percent. SAGE stock price is now 4.54% away from the 50-day moving average and 14.58% away from the 200-day moving average. The market capitalization of the company currently stands at $2.66B.
Will You Miss Out On This Growth Stock Boom?
A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.
And this is just one of our
5 Best Growth Stocks To Own For 2023.
Sponsored
In total, 12 analysts have assigned it a hold rating, and 10 have given it a buy rating. Brokers who have rated the stock have averaged $57.26 as their price target over the next twelve months.
On November 01, 2022, Loop Capital recently initiated its ‘Hold’ rating on the stock quoting a target price of $41, while ‘Berenberg’ rates the stock as ‘Hold’.
In other news, JONAS JEFFREY M, Director sold 11,643 shares of the company’s stock on Feb 10. The stock was sold for $519,413 at an average price of $44.61. Upon completion of the transaction, the Director now directly owns 121,981 shares in the company, valued at $5.42 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Nov 10, President and CEO Greene Barry E bought 14,500 shares of the business’s stock. A total of $500,022 was incurred on buying the stock at an average price of $34.48. This leaves the insider owning 46,940 shares of the company worth $2.09 million. Insiders disposed of 6,567 shares of company stock worth roughly $0.29 million over the past 1 year. A total of 0.10% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in SAGE stock. A new stake in Sage Therapeutics Inc. shares was purchased by CAMBER CAPITAL MANAGEMENT LP during the first quarter worth $28,525,000. SATURN V CAPITAL MANAGEMENT LLC invested $6,360,000 in shares of SAGE during the first quarter. In the first quarter, JANE STREET GROUP, LLC acquired a new stake in Sage Therapeutics Inc. valued at approximately $3,651,000. SCHRODER INVESTMENT MANAGEMENT GROUP acquired a new stake in SAGE for approximately $2,338,000. ERGOTELES LLC purchased a new stake in SAGE valued at around $2,040,000 in the second quarter. In total, there are 308 active investors with 88.70% ownership of the company’s stock.
With an opening price of $41.50 on Wednesday morning, Sage Therapeutics Inc. (NASDAQ: SAGE) set off the trading day. During the past 12 months, Sage Therapeutics Inc. has had a low of $27.36 and a high of $49.56. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 13.50, and a quick ratio of 13.50. The fifty day moving average price for SAGE is $42.49 and a two-hundred day moving average price translates $38.77 for the stock.
The latest earnings results from Sage Therapeutics Inc. (NASDAQ: SAGE) was released for Sep, 2022. According to the Biotechnology Company, earnings per share came in at -$2.31, missing analysts’ expectations of -$2.21 by -0.1. This compares to -$2.12 EPS in the same period last year. The company reported revenue of $2.86 million for the quarter, compared to $1.64 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 74.42 percent. For the current quarter, analysts expect SAGE to generate $1.94M in revenue.
Sage Therapeutics Inc.(SAGE) Company Profile
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company’s product pipeline also includes zuranolone, a neuroactive steroid, which is in Phase III clinical trials for treating PPD, major depressive disorders, treatment resistant disorders, generalized anxiety disorders, and bipolar depression; and SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson’s diseases. In addition, its product pipeline comprises SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which has completed Phase I clinical trial for the treatment of depression, Huntington’s disease, Alzheimer’s disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. Sage Therapeutics, Inc. has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of zuranolone in Japan, Taiwan, and South Korea; and a collaboration and license agreement with Biogen MA Inc. to jointly develop and commercialize SAGE-217 and SAGE-324 products. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.
